title: The management of aspirin in transurethral prostatectomy: current practice in the UK.
abstract: BACKGROUND
  Stopping aspirin prior to transurethral prostatectomy (TURP) may minimise peri-operative blood loss, but it may also increase the risk of a significant cardiovascular event. There are no guidelines on the management of aspirin in TURP. This study sought to determine the variation in the peri-operative management of transurethral prostatectomy (TURP) patients that are taking aspirin.
  
  
  METHODS
  A questionnaire was sent to 444 consultant urologists in the UK from a list obtained from the British Association of Urologists. This resulted in 290 anonymous replies (65%), of which 287 were suitable for analysis.
  
  
  RESULTS
  Of these 287 urologists, 178 (62%) ask patients to stop aspirin prior to TURP. Aspirin is stopped 9.8 days (median, 10 days; range, 2-30 days) prior to surgery, and recommenced 8.8 days (median, 7 days; range, 1-42 days) after surgery. In those that stop aspirin, 62% will stop aspirin in all patients, regardless of the indication, and 40% will cancel a TURP if aspirin use has inadvertently continued. Of the 287 urologists, 109 (38%) do not stop aspirin.
  
  
  CONCLUSIONS
  There is a wide variation in the management of aspirin in TURP patients in the UK. Aspirin is being stopped in patients at high risk of serious cardiovascular disease, often for longer than necessary. There is a need for multidisciplinary guidelines to reduce variation in practice.
authors.affiliation: Department of Urology, St Bartholomew's Hospital, London, UK. mkenver@hotmail.com
authors.forename: Mohamed Khalid
authors.initials: MK
authors.lastname: Enver
authors.forename: Ivan
authors.initials: I
authors.lastname: Hoh
authors.forename: Frank I
authors.initials: FI
authors.lastname: Chinegwundoh
mesh_terms: D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D010818:Practice Patterns, Physicians'; D011469:Prostatic Diseases / Q000601:surgery*; D012307:Risk Factors; D011795:Surveys and Questionnaires; D020728:Transurethral Resection of Prostate
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin